Asset Details
Do you wish to reserve the book?
Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma
Do you wish to request the book?
Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma
2017
Overview
The use of benralizumab, a monoclonal antibody directed against the alpha subunit of the interleukin-5 receptor, allowed patients with asthma who were dependent on oral glucocorticoids to reduce the glucocorticoid dose to a greater extent than those who received placebo.
Asthma is a common chronic inflammatory disease of the airways that affects an estimated 315 million persons worldwide.
1
Approximately 5 to 10% of persons with asthma have a severe form of disease that is usually managed with high-dose inhaled glucocorticoids and bronchodilators.
2
,
3
Within this group, 32 to 45% of persons rely on frequent or maintenance use of oral glucocorticoid therapy.
4
,
5
Oral glucocorticoid therapy adversely affects health-related quality of life,
6
and effective alternative therapies without severe adverse effects are needed.
Eosinophilic inflammation is a key part of asthma, and increased numbers of circulating and airway eosinophils are accompanied by . . .
Publisher
Massachusetts Medical Society
Subject
/ Adult
/ Anti-Asthmatic Agents - administration & dosage
/ Anti-Asthmatic Agents - adverse effects
/ Anti-Asthmatic Agents - therapeutic use
/ Antibodies, Monoclonal, Humanized - adverse effects
/ Antibodies, Monoclonal, Humanized - therapeutic use
/ Asthma
/ Dose-Response Relationship, Drug
/ Female
/ Glucocorticoids - administration & dosage
/ Humans
/ Interleukin-5 Receptor alpha Subunit - antagonists & inhibitors
/ Lungs
/ Male
